James C. Hamilton Sells 32,729 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) insider James C. Hamilton sold 32,729 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $19.82, for a total value of $648,688.78. Following the completion of the transaction, the insider now directly owns 272,122 shares in the company, valued at $5,393,458.04. The trade was a 10.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Arrowhead Pharmaceuticals Stock Up 0.4 %

NASDAQ:ARWR opened at $19.75 on Thursday. The company has a market cap of $2.46 billion, a PE ratio of -3.93 and a beta of 0.97. The stock has a 50-day simple moving average of $21.04 and a 200 day simple moving average of $22.55. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $17.05 and a 52-week high of $39.83.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Values First Advisors Inc. bought a new position in Arrowhead Pharmaceuticals in the third quarter valued at $52,000. Meeder Asset Management Inc. boosted its stake in shares of Arrowhead Pharmaceuticals by 4,629.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after buying an additional 3,333 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 788 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $149,000. Finally, Quarry LP raised its holdings in Arrowhead Pharmaceuticals by 54.5% during the second quarter. Quarry LP now owns 8,500 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 3,000 shares in the last quarter. 62.61% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ARWR has been the topic of several recent analyst reports. Citigroup reduced their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. Sanford C. Bernstein reduced their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research report on Friday, November 29th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, December 20th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $43.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.